By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – PGXL Labs today announced a partnership for the use of AutoGenomics' Infiniti Analyzer for several personal medicine applications.

PGXL plans to use the Infiniti Warfarin assay and the CYP450 assay, both of which have been cleared by the US Food and Drug Administration, as well as the Infiniti KRAS-BRAF test, it said.

AutoGenomics' Infiniti Analyzer is a microarray-based molecular diagnostics platform for measuring multiple signals from clinical samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.